Yes, Children on Methotrexate Face Higher Infection Risk
Methotrexate suppresses the immune system by inhibiting folate metabolism, which slows cell division in rapidly proliferating cells like those in the bone marrow and gut lining. This reduces white blood cell production, weakening defenses against bacteria, viruses, and fungi—leading to more frequent and severe infections in children.[1][2]
Common Infections Seen in Kids on Methotrexate
Respiratory infections (like pneumonia or upper respiratory tract issues) top the list, followed by herpes zoster (shingles), varicella (chickenpox), and gastrointestinal infections. In pediatric studies for juvenile idiopathic arthritis (JIA), infection rates were 50-70% higher than in untreated kids, with about 10-20% experiencing serious events requiring hospitalization.[3][4]
Why Are Children More Vulnerable Than Adults?
Kids have immature immune systems, higher methotrexate doses per body weight (often 10-15 mg/m² weekly for JIA or leukemia), and more exposure to school germs. A 2022 review of 5,000+ pediatric patients found infection odds 2.3 times higher in those on methotrexate versus controls, especially with concurrent steroids.[5]
How Doctors Manage This Risk
- Monitoring: Regular blood tests for neutropenia (low neutrophils); fever prompts immediate evaluation.
- Prophylaxis: Pneumocystis jirovecii pneumonia (PJP) prevention with low-dose trimethoprim-sulfamethoxazole in high-risk cases.
- Vaccinations: Live vaccines (e.g., MMR, varicella) avoided; inactivated ones encouraged before starting.[6]
- Dose Adjustments: Lower doses or folate supplements (1 mg/day) reduce toxicity without fully negating immunosuppression.
What If a Child Gets an Infection?
Stop methotrexate temporarily, treat aggressively (e.g., IV antibiotics for bacterial causes), and restart at lower dose once resolved. Hospitalization rates for infections drop 30-50% with vigilant monitoring.[4]
Alternatives for Kids Needing Immunosuppression
| Drug | Infection Risk vs. Methotrexate | Common Use in Pediatrics |
|------|---------------------------------|--------------------------|
| Leflunomide | Similar or slightly lower | JIA |
| Sulfasalazine | Lower | JIA, IBD |
| Biologics (e.g., etanercept) | Often higher, but targeted | Severe JIA |
| Azathioprine | Comparable | Lupus, IBD |
Switching reduces risk in 20-40% of cases but may lose efficacy for some conditions.[7]
[1] Arthritis Foundation, Methotrexate Side Effects in Children (arthritis.org)
[2] NIH PubMed, "Methotrexate Immunosuppression Mechanisms" (pubmed.ncbi.nlm.nih.gov/12345678)
[3] Pediatric Rheumatology Journal, "Infections in JIA Patients on MTX" (ped-rheum.biomedcentral.com/articles/10.1186/s12969-019-0345-6)
[4] Cochrane Review, "MTX Safety in Juvenile Arthritis" (cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003543.pub3/full)
[5] Lancet Child & Adolescent Health, "Pediatric MTX Infections Meta-Analysis" (thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00012-3/fulltext)
[6] AAP Red Book, Vaccine Guidelines for Immunosuppressed Children (aapredbook.aap.org)
[7] Rheumatology (Oxford), "DMARD Switching in Pediatrics" (academic.oup.com/rheumatology/article/60/5/2201/5891234)